Triple-Negative Breast Cancer

Nearly 75% of women treated with a novel vaccine designed to prevent triple-negative breast cancer achieved an immune response, according to updated results of a phase 1 trial.

SAN ANTONIO — The addition of camrelizumab to platinum-containing intensive neoadjuvant chemotherapy improved pathologic complete response for certain patients with triple-negative breast cancer.

SAN ANTONIO — In this video, Shimoli Barot, MD, discusses the results of a study observing exceptional treatment response in patients with metastatic breast cancer presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Combining a poly(ADP-ribose) polymerase inhibitor with a PD-1 antibody in a nonchemotherapy regimen for BRCA-mutated breast cancer showed promise, according to a presenter here.

SAN ANTONIO — A randomized phase 3 clinical trial designed to assess whether circulating tumor DNA surveillance could be used to help prevent breast cancer recurrence closed early due to a lack of patients eligible for randomization.

Sara M. Tolaney, MD, MPH, breast medical oncologist from Dana-Farber Cancer Institute, talked about survival data from KEYNOTE-522 that have been awaited with “a lot of anticipation.”

Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, discussed exciting OS data from the KEYNOTE-522 study presented at ESMO Congress.

Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.

Despite years of study and advances in breast cancer treatment, Otis Brawley, MD, professor of oncology at Johns Hopkins School of Medicine, said the disparity between the mortality rates of Black and white patients has never been greater.

BOSTON — Tumor samples from Black women diagnosed with triple-negative breast cancer expressed higher levels of insulin signaling than samples from white women, suggesting hyperinsulinemia may play a role in disease outcomes, data show.